Electromagnetic Mechanical Clot Detection/Chromogenic Assay/Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)
This test is the preferred initial panel for the evaluation of suspected antiphospholipid syndrome. This reflex panel provides a multistep combination of assays.
Test Description
Test Components and Reflex Patterns
When the Antiphospholipid Syndrome Reflex Panel is ordered, three initial tests will always be ordered and performed by ARUP. These tests are also available separately.
Test | Method | Standalone Test Code |
---|---|---|
Beta-2 Glycoprotein 1 Antibodies, IgG and IgM | Semi-quantitative enzyme-linked immunosorbent assay | 0050321 |
Cardiolipin Antibodies, IgG and IgM | Semi-quantitative enzyme-linked immunosorbent assay | 0099344 |
Lupus Anticoagulant Reflex Panel | Electromagnetic mechanical clot detection/chromogenic assay | 3017009 |
Based on the results of the above assays, the following tests may be performed by reflex (additional charges apply):
Reflex Reason | Test Added (Code) |
---|---|
Specific findings within the Lupus Anticoagulant Reflex Panel | Refer to the Lupus Anticoagulant Reflex Panel Test Fact Sheet for information about the Lupus Anticoagulant Reflex Panel (3017009) |
Test Interpretation
Sensitivity/Specificity
Varies
Results
Interpretive information, including the reference interval, is provided for each test component. Refer to the Example Reports on the ARUP Laboratory Test Directory for more information. For more information about anticoagulant neutralization in the lupus anticoagulant panel, refer to the Lupus Anticoagulant Reflex Panel Test Fact Sheet.
Limitations
- Results should be interpreted within the context of a patient’s complete clinical picture.
- The following factors may result in test interference or spurious results:
- Acute phase reactions due to pregnancy, malignancy, inflammatory or infectious states, or trauma
- Liver disease
- Anticoagulant medications in concentrations exceeding the capacity of neutralizing reagents (heparins, direct oral anticoagulants [DOACs])
- Warfarin effect
- Residual platelets (≥10,000 platelets/uL) in the plasma sample
- Specific factor antibodies directed against clotting factors involved in the intrinsic or common pathways.